SBI-0640756 is a first-in-class eIF4G1 inhibitor that disrupts the eIF4F complex; it inhibits the growth of BRAF-resistant and BRAF-dependent melanoma; suppresses AKT and NF-κB signaling pathways; inhibits the growth of melanoma harboring NRAS, BRAF, and NF1 mutations in vitro; and delays onset and reduces incidence of Nras/Ink4a melanoma in vivo.